Open AccessModern treatment of ALK-positive non-small cell lung cancer
Author(s) -
Dmitry A. Kharagezov,
Yu. N. Lazutin,
E. A. Mirzoyan,
Anton G. Milakin,
O. N. Stateshny,
Igor A. Leyman,
Yu. N. Lazutin,
V. N. Vitkovskaya,
K. D. Iozefi
Publication year - 2022
Publication title -
ûžno-rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-9039
pISSN - 2687-0533
DOI - 10.37748/2686-9039-2022-3-2-5
Subject(s) - anaplastic lymphoma kinase , alectinib , lung cancer , medicine , crizotinib , oncology , stage (stratigraphy) , alk inhibitor , ceritinib , ros1 , targeted therapy , chemotherapy , cancer , adenocarcinoma , biology , paleontology , malignant pleural effusion